Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04999280
Other study ID # CROMA
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2021
Est. completion date June 30, 2022

Study information

Verified date January 2023
Source Federico II University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to evaluate the effect of a daily consumption for 2 weeks of a sourdough croissant enriched with dietary fibers vs a control sourdough croissant with no fiber added on daily energy intakes, fasting metabolic parameters, inflammatory status, blood pressure, anthropometric measures, body composition, appetite sensations, gastrointestinal functionality and gut microbiota composition.


Description:

Associations between human health, diet and gut microbiota composition and functionality have been widely highlighted by the scientific literature in this field. Evidence shows that population adopting a Western dietary model, with a reduced intake of dietary fiber, undergo an adaptation of the gut microbiota characterized by the loss of some bacterial species and a general reduction in microbial biodiversity. The national guidelines for a healthy diet suggest to include daily fruit, vegetables, whole grains and legumes (the main sources of fiber in the diet) in the habitual diet to reduce the risk of diseases and to improve health. However, the compliance with these nutritional recommendations is generally low among individuals. Therefore, the commercial availability of dietary fiber-enriched products could be advantageous. Breakfast is an important meal that should provide at least 20% of the daily calories with an adequate supply of all nutrients. Having fiber-enriched foods for breakfast could bring numerous nutritional benefits and if they are made with sourdough may be even better. Indeed, sourdough leavened baked products provide compounds with potential prebiotic activity, reduce the glucose and insulin response, increase satiety and reduce gastro-intestinal disorders upon consumption. The hypothesis is that the combination of sourdough and dietary fiber in baked products could further ameliorate glucose metabolism in consumers compared to sourdough products. The aim of this study is to evaluate the effects of a daily consumption at breakfast for 2 weeks of a sourdough croissant enriched with dietary fibers from 10 different sources vs a sourdough croissant with no fiber added (control) on daily energy intakes, metabolic and inflammatory status, appetite feelings, body weight, body mass index (BMI), waist and hip circumferences, body composition, blood pressure, gut microbiota composition and gastrointestinal functionality in healthy subjects.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date June 30, 2022
Est. primary completion date April 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - healthy subjects; - men and women; - age 18-50 years; - 20 kg/m2 = BMI = 35 kg/m2; - habitual daily breakfast consumption (= 250kcal/day); - habitual diet characterized by absence of any food supplements and alternative medication, probiotics and prebiotics, whole grain and/or fiber enriched foods; - intake of fruit/vegetables < 3 servings/day; - low level of physical activity; - signed written informed consent. Exclusion Criteria: - food allergies and intolerances and celiac disease; - gastrointestinal diseases; - relevant diseases; - pregnant or breastfeeding; - previous abdominal surgery; - hypertriglyceridemia (Triglycerides > 200 mg/dL); - hypercholesterolemia (Total cholesterol > 200 mg/dL); - hyperglycaemia (glycaemia = 110 mg/dL); - hypertension (arterial blood pressure =140/90 mm Hg); - weight loss = 3 kg within 2 months before the study; - antibiotics treatment within 3 months before the study; - any medication (different from antibiotics) at the enrollment and within 2 months before the study; - habitual diet characterized by high fruit and vegetables intakes (>3 portion/die); - high level of physical activity; - alcohol consumption = 3 alcohol units per day; - simultaneous participation in other trial.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Fiber Croissant (FIBCRO) Group
Subjects will consume for 2 weeks at breakfast a fiber-enriched sourdough croissant. All subjects will be requested not to change other dietary habits and their physical activity during the 2 week intervention period.
Control Croissant (CONCRO) Group
Subjects will consume for 2 weeks at breakfast a sourdough croissant. All subjects will be requested not to change other dietary habits and their physical activity during the 2 week intervention period.

Locations

Country Name City State
Italy Department of Agricultural Sciences, Federico II University Portici

Sponsors (1)

Lead Sponsor Collaborator
Federico II University

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Variation of daily energy intakes Calculation of total daily energy intakes based on 7 days food records 2 weeks
Secondary Changes in fasting plasma inflammatory markers Measure of plasma C-reactive protein (mmol/L) 2 weeks
Secondary Changes in fasting plasma lipids Measure of plasma concentrations (mg/dL) of Total-, LDL-, and HDL-Cholesterol, as well as Triglycerides 2 weeks
Secondary Changes in fasting blood glucose Measure of blood glucose concentrations (mg/dL) 2 weeks
Secondary Variation of serum Insulin hormone concentration Measure of serum Insulin concentrations (mg/dL) 2 weeks
Secondary Variation of plasma endocannabinoids and N-acyl-ethanolamines concentration Measure of plasma endocannabinoids and N-acyl-ethanolamines concentrations (mg/dL) 2 weeks
Secondary Variation of serum dipeptidyl-dipeptidase-IV activity Measure of serum dipeptidyl-dipeptidase-IV (U/L) activity 2 weeks
Secondary Variation of urinary excretion levels of polyphenols Measure of polyphenols concentration in urine by mean of liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS) 2 weeks
Secondary Variation of urinary excretion levels of urolithins Measure of urolithins concentration in urine by mean of LC/MS/MS 2 weeks
Secondary Changes in stool consistency Measure of consistency of feces by mean of King's stool chart filled out by subjects. The chart comprises four categories of stool consistency: hard and formed, soft and formed, loose and unformed, liquid. 2 weeks
Secondary Changes in stool weight Measure of stool weight by mean of King's stool chart filled out by subjects. The chart comprises three categories of stool weight : <100 g, 100-200 g, >200 g. 2 weeks
Secondary Changes in stool frequency Measure of frequency of feces by mean of King's stool chart filled out by subjects. Fecal frequency is incorporated by recording the code of each feces passed over a 24 hour period. 2 weeks
Secondary Changes in gastrointestinal functionality Calculation of daily fecal score from summation of all scores for stool consistency, weight and frequency obtained from King's stool chart filled out by subjects. Scores are weighted such that an increase in fecal frequency alone results in a higher score than a change in fecal consistency alone, which in turn results in a higher score than an increase in fecal weight alone. Diarrhea is classified by a daily fecal score of 15 or more. 2 weeks
Secondary Changes in faecal microbiome The composition of faecal microbiome will be determined by high throughput sequencing of the ribosomal ribonucleic acid 16S (16S rRNA) gene. The massive number of sequences obtained will be analyzed by using state of the art bioinformatics tools and the presence and relative abundance of the microbial species occurring in each sample will be determined. 2 weeks
Secondary Changes in body weight Measure of body weight in fasting subjects 2 weeks
Secondary Changes in body mass index Calculation of body mass index by using the formula weight in kilograms divided by height in meters squared. 2 weeks
Secondary Changes in waist circumference Measure of waist circumference at the midpoint between the lower margin of the least palpable rib and the top of the iliac crest. 2 weeks
Secondary Changes in hip circumference Measure of hip circumference around the widest portion of the buttocks. 2 weeks
Secondary Changes in blood pressure Measure of systolic pressure and diastolic pressure in millimetres of mercury (mmHg) by using a digital sphygmomanometer 2 weeks
Secondary Changes in body composition Body composition is determined by conventional bioelectrical impedance analysis with a single-frequency 50 kilohertz (kHz) bioelectrical impedance analyzer in the postabsorptive state (fasting subjects) and after being in the supine position for 20 min. Body composition data will be calculated from bioelectrical measurements and anthropometric data by using validated predictive equations. 2 weeks
Secondary Variation of hunger feeling scores Measures of hunger sensation over the day reported by subjects by using hunger Visual Analogue Scales (VAS) 0-10 centimeters (where 0 corresponds to the lowest and 10 to the highest feeling the individual could perceive). Changes in these scores may reflect potential effects of dietary intervention in modulating hunger. 2 weeks
Secondary Variation of fullness feeling scores Measure of fullness sensation over the day reported by subjects by using fullness Visual Analogue Scales (VAS) 0-10 centimeters (where 0 corresponds to the lowest and 10 to the highest feeling the individual could perceive). Changes in these scores may reflect potential effects of dietary intervention in modulating fullness. 2 weeks
Secondary Variation of satiety feeling scores Measure of satiety sensation over the day reported by subjects by using satiety Visual Analogue Scales (VAS) 0-10 centimeters (where 0 corresponds to the lowest and 10 to the highest feeling the individual could perceive). Changes in these scores may reflect potential effects of dietary intervention in modulating satiety. 2 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1